Nanobiotix appoints CordenPharma as CMO for potential nanoparticle-based cancer treatment
The deal comes as CordenPharma plans to open a new manufacturing line at its France site, which is one of eight cGMP facilities across Europe and the US, and the new line will increase production capacity 25-fold.
The new line is expected manufacture NBTXR3, Nanobiotix’s lead product, which is comprised of Hafnium Oxide nanoparticles that can be injected directly into tumors. With the application of radiotherapy, these nanoparticles absorb X-rays and have the potential to significantly enhance the radiation dose within the cancer cells without increasing the dose to the surrounding healthy tissues, the company says.
Nanobiotix expects its product to win CE marking in 2016, and is therefore preparing to scale-up production to meet the needs of the expected commercialization. The company also anticipates future demand from clinical trials in the coming years in Europe and the US.
Yves Michon, president of CordenPharma said: “Nanobiotix’s product, NBTXR3 is a fascinating product – not only with respect to its properties, but also in its manufacture. We are working closely with Nanobiotix to ensure a seamless process and manage the scale-up of the product.”
